ICD-11 code : XM7P50;
Preferred Label : Ebola vaccines;
ICD-11 definition : Two types of Ebola vaccines have been licensed and prequalified by WHO – the live,
attenuated, single-dose rVSV G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) and the heterologous,
two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutical).
Both are recommended against Ebola virus disease. They are not recommended against
disease cause by other virus of the Orthoebolavirus genus. The single-dose single-dose
rVSV G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) is recommended for both outbreak response
and preventive vaccination of health care and frontline workers in at-risk countries.
A stockpile of vaccine doses has been established for reactive use and is management
by the International Coordinating Group for vaccine provision. The two-dose Ad26.ZEBOV
and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutica) is recommended
for preventive use, outside of an outbreak response, in health care and frontline
workers in at-risk countries. For more recommendation, see SAGE recommendations https://iris.who.int/bitstream/handle/10665/378109/WER9927-355-362.pdf?sequence
1&isAllowed y;
Origin ID : 2084009990;
Currated CISMeF NLP mapping
Two types of Ebola vaccines have been licensed and prequalified by WHO – the live,
attenuated, single-dose rVSV G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) and the heterologous,
two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutical).
Both are recommended against Ebola virus disease. They are not recommended against
disease cause by other virus of the Orthoebolavirus genus. The single-dose single-dose
rVSV G-ZEBOV-GP vaccine (Ervebo, Merck & Co.) is recommended for both outbreak response
and preventive vaccination of health care and frontline workers in at-risk countries.
A stockpile of vaccine doses has been established for reactive use and is management
by the International Coordinating Group for vaccine provision. The two-dose Ad26.ZEBOV
and MVA-BN-Filo vaccine regimen (Zabdeno and Mvabea, Janssen Pharmaceutica) is recommended
for preventive use, outside of an outbreak response, in health care and frontline
workers in at-risk countries. For more recommendation, see SAGE recommendations https://iris.who.int/bitstream/handle/10665/378109/WER9927-355-362.pdf?sequence
1&isAllowed y
